Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 256

1.

HER2 Codon 655 (Ile/Val) Polymorphism and Breast Cancer in Austrian Women.

Watrowski R, Castillo-Tong DC, Wolf A, Schuster E, Fischer MB, Speiser P, Zeillinger R.

Anticancer Res. 2015 Nov;35(11):5901-4.

PMID:
26504013
2.

HER2 Codon 655 (Ile/Val) Polymorphism and Breast Cancer in Austrian Women.

Watrowski R, Castillo-Tong DC, Wolf A, Schuster E, Fischer MB, Speiser P, Zeillinger R.

Anticancer Res. 2015 Dec;35(12):6667-70.

PMID:
26637882
3.

MiR-4728-3p could act as a marker of HER2 status.

Li H, Zhou X, Zhu J, Cheng W, Zhu W, Shu Y, Liu P.

Cancer Biomark. 2015;15(6):807-14. doi: 10.3233/CBM-150524.

PMID:
26406406
4.

Identification of Novel Breast Cancer Risk Loci.

Chan CHT, Munusamy P, Loke SY, Koh GL, Wong ESY, Law HY, Yoon CS, Tan MH, Yap YS, Ang P, Lee ASG.

Cancer Res. 2017 Oct 1;77(19):5428-5437. doi: 10.1158/0008-5472.CAN-17-0992. Epub 2017 Aug 3.

5.

Clinicopathological significance of β -tubulin isotype III gene expression in breast cancer patients.

He Q, Peng B, Zhuang D, Xiao L, Zheng L, Fan Z, Zhu J, Xu B, Xu C, Zhao J, Wu L, Zhou P, Hou L, Yu F, Zhao G.

Cancer Biomark. 2015;15(6):823-31. doi: 10.3233/CBM-150526.

PMID:
26406408
6.

Factors influencing the hormone receptor and HER2 levels in breast cancer: a population-based analysis.

Tas F.

Onkologie. 2012;35(3):95-8. doi: 10.1159/000336812. Epub 2012 Feb 21.

PMID:
22414972
7.

Association of HER2 codon 655 polymorphism with ovarian cancer.

Watrowski R, Castillo-Tong DC, Schuster E, Fischer MB, Speiser P, Zeillinger R.

Tumour Biol. 2016 Jun;37(6):7239-44. doi: 10.1007/s13277-015-4609-2. Epub 2015 Dec 14.

PMID:
26666819
8.

Association of Estrogen Receptor Alpha and Interleukin 6 Polymorphisms with Lymphovascular Invasion, Extranodal Extension, and Lower Disease-Free Survival in Thai Breast Cancer Patients.

Sa-Nguanraksa D, Suntiparpluacha M, Kulprom A, Kummalue T, Chuangsuwanich T, Avirutnan P, O-Charoenrat P.

Asian Pac J Cancer Prev. 2016;17(6):2935-40.

9.

Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer.

Karsten M, Stempel M, Radosa J, Patil S, King TA.

Ann Surg Oncol. 2016 Feb;23(2):471-6. doi: 10.1245/s10434-015-4841-4. Epub 2015 Sep 4.

10.

Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers.

Kuchenbaecker KB, Neuhausen SL, Robson M, Barrowdale D, McGuffog L, Mulligan AM, Andrulis IL, Spurdle AB, Schmidt MK, Schmutzler RK, Engel C, Wappenschmidt B, Nevanlinna H, Thomassen M, Southey M, Radice P, Ramus SJ, Domchek SM, Nathanson KL, Lee A, Healey S, Nussbaum RL, Rebbeck TR, Arun BK, James P, Karlan BY, Lester J, Cass I; Breast Cancer Family Registry, Terry MB, Daly MB, Goldgar DE, Buys SS, Janavicius R, Tihomirova L, Tung N, Dorfling CM, van Rensburg EJ, Steele L, v O Hansen T, Ejlertsen B, Gerdes AM, Nielsen FC, Dennis J, Cunningham J, Hart S, Slager S, Osorio A, Benitez J, Duran M, Weitzel JN, Tafur I, Hander M, Peterlongo P, Manoukian S, Peissel B, Roversi G, Scuvera G, Bonanni B, Mariani P, Volorio S, Dolcetti R, Varesco L, Papi L, Tibiletti MG, Giannini G, Fostira F, Konstantopoulou I, Garber J, Hamann U, Donaldson A, Brewer C, Foo C, Evans DG, Frost D, Eccles D; EMBRACE Study, Douglas F, Brady A, Cook J, Tischkowitz M, Adlard J, Barwell J, Ong KR, Walker L, Izatt L, Side LE, Kennedy MJ, Rogers MT, Porteous ME, Morrison PJ, Platte R, Eeles R, Davidson R, Hodgson S, Ellis S, Godwin AK, Rhiem K, Meindl A, Ditsch N, Arnold N, Plendl H, Niederacher D, Sutter C, Steinemann D, Bogdanova-Markov N, Kast K, Varon-Mateeva R, Wang-Gohrke S, Gehrig A, Markiefka B, Buecher B, Lefol C, Stoppa-Lyonnet D, Rouleau E, Prieur F, Damiola F; GEMO Study Collaborators, Barjhoux L, Faivre L, Longy M, Sevenet N, Sinilnikova OM, Mazoyer S, Bonadona V, Caux-Moncoutier V, Isaacs C, Van Maerken T, Claes K, Piedmonte M, Andrews L, Hays J, Rodriguez GC, Caldes T, de la Hoya M, Khan S, Hogervorst FB, Aalfs CM, de Lange JL, Meijers-Heijboer HE, van der Hout AH, Wijnen JT, van Roozendaal KE, Mensenkamp AR, van den Ouweland AM, van Deurzen CH, van der Luijt RB; HEBON, Olah E, Diez O, Lazaro C, Blanco I, Teulé A, Menendez M, Jakubowska A, Lubinski J, Cybulski C, Gronwald J, Jaworska-Bieniek K, Durda K, Arason A, Maugard C, Soucy P, Montagna M, Agata S, Teixeira MR; KConFab Investigators, Olswold C, Lindor N, Pankratz VS, Hallberg E, Wang X, Szabo CI, Vijai J, Jacobs L, Corines M, Lincoln A, Berger A, Fink-Retter A, Singer CF, Rappaport C, Kaulich DG, Pfeiler G, Tea MK, Phelan CM, Mai PL, Greene MH, Rennert G, Imyanitov EN, Glendon G, Toland AE, Bojesen A, Pedersen IS, Jensen UB, Caligo MA, Friedman E, Berger R, Laitman Y, Rantala J, Arver B, Loman N, Borg A, Ehrencrona H, Olopade OI, Simard J, Easton DF, Chenevix-Trench G, Offit K, Couch FJ, Antoniou AC; CIMBA.

Breast Cancer Res. 2014 Dec 31;16(6):3416. doi: 10.1186/s13058-014-0492-9.

11.

Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.

Kuzhan A, Adli M, Eryigit Alkis H, Caglayan D.

J BUON. 2013 Jul-Sep;18(3):619-22.

12.

Low protein expression of MET in ER-positive and HER2-positive breast cancer.

Zagouri F, Brandstetter A, Moussiolis D, Chrysikos D, Dimitrakakis C, Tsigginou A, Marinopoulos S, Zografos GC, Sergentanis TN, Dimopoulos MA, Filipits M.

Anticancer Res. 2014 Mar;34(3):1227-31.

PMID:
24596364
13.

Predicting early brain metastases based on clinicopathological factors and gene expression analysis in advanced HER2-positive breast cancer patients.

Duchnowska R, Jassem J, Goswami CP, Dundar M, Gökmen-Polar Y, Li L, Woditschka S, Biernat W, Sosińska-Mielcarek K, Czartoryska-Arłukowicz B, Radecka B, Tomasevic Z, Stępniak P, Wojdan K, Sledge GW Jr, Steeg PS, Badve S.

J Neurooncol. 2015 Mar;122(1):205-16. doi: 10.1007/s11060-014-1704-y. Epub 2015 Jan 6.

14.

Breast Cancer Molecular Subtypes Defined by ER/PR and HER2 Status: Association with Clinicopathologic Parameters in Ivorian Patients.

Effi AB, Aman NA, Koui BS, Koffi KD, Traore ZC, Kouyate M.

Asian Pac J Cancer Prev. 2016;17(4):1973-8.

15.
16.

Apoptosis-, proliferation, immune function-, and drug resistance- related genes in ER positive, HER2 positive and triple negative breast cancer.

Kolacinska A, Chalubinska J, Zawlik I, Szymanska B, Borowska-Garganisz E, Nowik M, Fendler W, Kubiak R, Pawlowska Z, Morawiec Z, Szemraj J.

Neoplasma. 2012;59(4):424-32. doi: 10.4149/neo_2012_055.

PMID:
22489698
17.

HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites.

Millikan R, Eaton A, Worley K, Biscocho L, Hodgson E, Huang WY, Geradts J, Iacocca M, Cowan D, Conway K, Dressler L.

Breast Cancer Res Treat. 2003 Jun;79(3):355-64.

PMID:
12846420
18.
19.

Hormone receptors and HER2 expression in primary breast carcinoma and corresponding lymph node metastasis: do we need both?

Raica M, Cîmpean AM, Ceausu RA, Fulga V, Nica C, Rudico L, Saptefrati L.

Anticancer Res. 2014 Mar;34(3):1435-40.

PMID:
24596391
20.

Is breast cancer from Sub Saharan Africa truly receptor poor? Prevalence of ER/PR/HER2 in breast cancer from Kenya.

Sayed S, Moloo Z, Wasike R, Bird P, Oigara R, Govender D, Kibera J, Carrara H, Saleh M.

Breast. 2014 Oct;23(5):591-6. doi: 10.1016/j.breast.2014.06.006. Epub 2014 Jul 7.

PMID:
25012047

Supplemental Content

Support Center